Please login to the form below

Not currently logged in
Email:
Password:

Teva launches first generic of GSK's Lovaza in US

Will have six months of marketing exclusivity for copy of cardiovascular drug
Teva Pharma logo

Israel-based Teva Pharmaceutical Industries has won US FDA approval for a generic equivalent to GlaxoSmithKline's fish-oil derived cardiovascular product Lovaza and will launch it immediately.

Teva said it believes it is the first company to file for approval of generic Lovaza (omega-3-acid ethyl esters capsules) and the first to secure marketing approval, which should give it six months of marketing exclusivity on the US market.

Lovaza is used to lower triglyceride levels in patients with cardiovascular disease and has annual sales of around $1.1bn in the US, according to IMS data cited by Teva. GSK acquired US rights to Lovaza - which was originally developed by Norway's Pronova BioPharma - when it took over Reliant Pharmaceuticals in 2008 for $1.7bn.

Last year, the US Court of Appeals for the Federal Circuit cleared the way for generic versions of Lovaza, ruling that both Teva and Par Pharmaceuticals could proceed with plans to launch generic copies of Lovaza.

An earlier settlement between ProNova and Apotex gave the generics company rights to launch its own generic in the US early in 2015.

Aside from GSK, the launch of a lower-priced Lovaza generic in the US also impacts Amarin Pharmaceuticals' Vascepa (icosapent ethyl), another fish oil-based therapy that is already on the market but was turned down by the FDA last October for use alongside statin drugs. Sales of Vascepa were around $26m in 2013, its first year on the market.

Also affected is AstraZeneca, which filed for approval of its own triglyceride-lowering drug Epanova last year. AZ acquired Epanova along with developer Omthera Pharmaceuticals in July 2013 in a $443m deal.

Article by
Phil Taylor

9th April 2014

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
Women are largely prescribed exactly the same treatment regimens as men, with no account for the underlying differences in physiology and drug metabolism between the sexes....
Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...

Infographics